Machine learning identifies molecular regulators and therapeutics for targeting SARS‐CoV2‐induced cytokine release

Machine learning identifies molecular regulators and therapeutics for targeting SARS‐CoV2‐induced cytokine release

Abstract Although 15–20% of COVID‐19 patients experience hyper‐inflammation induced by massive cytokine production, cellular triggers of this process and strategies to target them remain poorly understood. Here, we show that the N‐terminal domain (NTD) of the SARS‐CoV‐2 spike protein substantially i...

Full description

Saved in:
Bibliographic Details
Main Authors: Marina Chan, Siddharth Vijay, John McNevin, M Juliana McElrath, Eric C Holland, Taranjit S Gujral
Format: Article
Language:English
Published: Springer Nature 2021-09-01
Series:Molecular Systems Biology
Subjects:
kinases
machine learning
N‐terminal domain
Ponatinib
SARS‐CoV‐2
Online Access:https://doi.org/10.15252/msb.202110426
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Although 15–20% of COVID‐19 patients experience hyper‐inflammation induced by massive cytokine production, cellular triggers of this process and strategies to target them remain poorly understood. Here, we show that the N‐terminal domain (NTD) of the SARS‐CoV‐2 spike protein substantially induces multiple inflammatory molecules in myeloid cells and human PBMCs. Using a combination of phenotypic screening with machine learning‐based modeling, we identified and experimentally validated several protein kinases, including JAK1, EPHA7, IRAK1, MAPK12, and MAP3K8, as essential downstream mediators of NTD‐induced cytokine production, implicating the role of multiple signaling pathways in cytokine release. Further, we found several FDA‐approved drugs, including ponatinib, and cobimetinib as potent inhibitors of the NTD‐mediated cytokine release. Treatment with ponatinib outperforms other drugs, including dexamethasone and baricitinib, inhibiting all cytokines in response to the NTD from SARS‐CoV‐2 and emerging variants. Finally, ponatinib treatment inhibits lipopolysaccharide‐mediated cytokine release in myeloid cells in vitro and lung inflammation mouse model. Together, we propose that agents targeting multiple kinases required for SARS‐CoV‐2‐mediated cytokine release, such as ponatinib, may represent an attractive therapeutic option for treating moderate to severe COVID‐19.
ISSN:1744-4292

Similar Items